a cura di Cesare Gridelli & Filippo de Marinis
VISUALIZZAa cura di Cesare Gridelli & Filippo de Marinis
VISUALIZZAPhase I/II study of nivolumab with or without ipilimumab for treatment of recurrent SCLC: CA209-032
Phase III study randomized trial (ChekMate 057) of nivolumanb (NIVO) versus docetaxel (DOC) in advanced non-SQ NSCLC
Changes in the Standard of Care for Non¬¬-Small Cell Lung Cancer
A phase III study (ChekMate 017) of nivolumab (NIVO) versus docetaxel (DOC) in previously treated advanced or metastatic SQ NSCLC
Phase II studies of nivolumab in patients with advanced squamous or nonsquamous NSCLC